; (B) the 15 drugs with the highest total Federal spending across all such Federal programs; (C) any drugs with annual per-user spending under any such program, based on claims data analysis, that, for the first reporting year is $10,000 or more per user, and, in subsequent reporting years, is priced at or above the rate, as determined by the Secretary, that is $10,000, increased by the medical care consumer price index